1. TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background
   Maria V. Guijarro et al, 2023, Oncogene CrossRef
2. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
   Yajun Liu et al, 2024, Archives of Pharmacal Research CrossRef
3. Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
   Dean A. Fennell et al, 2020, Clinical Cancer Research CrossRef
4. The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
   Christophe Blanquart et al, 2020, Frontiers in Oncology CrossRef
5. A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma
   Hidenori Ando et al, 2020, Molecules CrossRef
6. A novel intraperitoneal therapy for gastric cancer with DFP‐10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model
   Hidenori Ando et al, 2019, Cancer Medicine CrossRef
7. Liposomes for Advanced Drug Delivery
   Amit Verma et al, 2020, Advanced Biopolymeric Systems for Drug Delivery CrossRef
8. Mouse models for mesothelioma drug discovery and development
   Kenneth P. Seastedt et al, 2021, Expert Opinion on Drug Discovery CrossRef
9. Development of efficient and safe drug delivery system with liposomes for clinical application ： 11^th Mizushima Award, Japan Society of DDS
   Tatsuhiro Ishida, 2018, Drug Delivery System CrossRef
10. Silencing of ATP11B by RNAi-Induced Changes in Neural Stem Cell Morphology
    Jiao Wang et al, 2017, RNAi and Small Regulatory RNAs in Stem Cells CrossRef
11. Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy
    Amr S. Abu Lila et al, 2016, Molecular Pharmaceutics CrossRef
12. Manufacturing of Oligonucleotides
    E. Paredes et al, 2017, Comprehensive Medicinal Chemistry III CrossRef
13. Overcoming barriers by local drug delivery with liposomes
    S.G. Antimisiaris et al, 2021, Advanced Drug Delivery Reviews CrossRef
14. CMC and regulatory aspects of oligonucleotide therapeutics
    Thomas M. Rupp et al, 2022, RNA Therapeutics CrossRef
15. Genomics and Functional Genomics of Malignant Pleural Mesothelioma
    Ece Cakiroglu et al, 2020, International Journal of Molecular Sciences CrossRef
16. An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers
    Hidenori Ando et al, 2020, Advanced Drug Delivery Reviews CrossRef